Irinotecan NEW
| Price | $29 | $40 | $58 |
| Package | 10mg | 25mg | 50mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Irinotecan | CAS No.: 97682-44-5 |
| Purity: 99.92% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Irinotecan |
| Description | Irinotecan (CPT-11), a derivative of camptothecin, is an inhibitor of DNA topoisomerase I (Topo I). Irinotecan has antitumor activity by preventing DNA strand reattachment through binding to the Topo I complex, resulting in double-stranded DNA breaks and cell death. |
| Cell Research | Irinotecan is dissolved in DMSO and stored, and then diluted with appropriate medium before use[1]. To determine the effects of Irinotecan in combination with 5-FU, the MTT assay is used. Depending on the cell lines, 10,000 to 20,000 cells per well are seeded in 96-well plates and incubated for 24 h in complete medium. On day 2, cells are incubated in the absence or presence of Irinotecan for 30 min followed by 5-FU for 24 h. After another 24 h in complete medium without any additives, MTT reagent is added on day 4 to initiate the assay and the cells are incubated for an additional 4 h at 37°C. After removal of the medium and dissolving the crystals with acidified isopropanol, the samples are analyzed using an ELISA plate reader at 570 nm. The value at 650 nm is subtracted as background[1]. |
| In vitro | METHODS: Human breast cancer cells MCF-7 were treated with Irinotecan (10-320 μg/mL) for 24-48 h. Cell viability was measured by trypan blue. RESULTS: Cell viability decreased to 85.5% at 10 μg/mL and 58% at 160 μg/mL with Irinotecan treatment for 24 h. Viability decreased to 33% at 160 μg/mL with Irinotecan treatment for 48 h. [1] METHODS: HCT116 p53+/+,hMLH1+, p53+/+,hMLH1- and p53-/-,hMLH1- were treated with Irinotecan (4.5 μM) for 48 h. Cell cycle profiles were analyzed by Flow Cytometry. RESULTS: Irinotecan treatment induced G2/M arrest of different durations in all three cell lines. The block was maintained for at least 12 days in the p53+/+, hMLH1+ cell lines. The slow release of the block in the p53+/+, hMLH1- cell line 6-9 days after treatment initiation suggests that the status of the hMLH1 molecule may indirectly or directly influence the maintenance of G2/M block. In the p53-/- cell line, G2/M block was terminated within 4 days of treatment initiation. [2] |
| In vivo | METHODS: To test the antitumor activity in vivo, Irinotecan (40 mg/kg) was administered intraperitoneally three times a week for four weeks to an NSG mouse model of MLL rearrangement ALL xenografts. RESULTS: Irinotecan effectively inhibited the growth of MLL rearrangement ALL in vivo. [3] METHODS: To assay anti-tumor activity in vivo, Irinotecan (10 mg/kg four times every four days or 40 mg/kg six times every four days) was administered intraperitoneally to swiss nu/nu mice bearing five CRC xenograft tumors. RESULTS: At low doses of Irinotecan, four of the five xenografts responded to Irinotecan with a growth delay of up to 10 days. At high doses of Irinotecan, five xenografts showed variable but significant responses. [4] |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 11 mg/mL (18.75 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.2 mg/mL (5.45 mM), Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. |
| Keywords | Inhibitor | CPT 11 | CPT11 | Topoisomerase | inhibit | Irinotecan | Autophagy |
| Inhibitors Related | Stavudine | Aceglutamide | Sodium 4-phenylbutyrate | Hydroxychloroquine | Guanidine hydrochloride | Taurine | Valproic Acid | Curcumin | Paeonol | Naringin | Salicylic acid | Gefitinib |
| Related Compound Libraries | Anti-Tumor Natural Product Library | Bioactive Compound Library | Alkaloid Natural Product Library | Drug Repurposing Compound Library | Natural Product Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/25kg |
Shaanxi Haibo Biotechnology Co., Ltd
|
2023-09-07 | ||
| $0.00/1kg |
VIP2Y
|
Hangzhou ICH Biofarm Co., Ltd
|
2023-06-26 | |
| $12.00/1KG |
XINGTAI XINGJIU NEW MATERIAL TECHNOLOGY CO., LTD
|
2021-12-20 | ||
| $0.00/25KG |
Hangzhou Huarong Pharm Co., Ltd.
|
2021-09-14 | ||
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-08 | ||
| $1.10/1g |
VIP4Y
|
Dideu Industries Group Limited
|
2021-07-02 | |
| $825.00/10g/Bag |
VIP4Y
|
Baoji Guokang Bio-Technology Co., Ltd.
|
2021-06-03 | |
| $0.00/1g |
VIP6Y
|
BOC Sciences
|
2020-05-15 | |
| $0.00/1Kg |
VIP6Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2020-04-30 | |
| $0.00/1g |
Beijing Yibai Biotechnology Co., Ltd
|
2019-08-28 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY